FILIPINO pharmaceutical company MedEthix went beyond its way as the first importer to secure from the Food and Drug Administration the compassionate special permit (CSP) for molnupiravir — an oral drug indicated for mild to moderate cases of Covid-19 infection, which then enabled the standard of care to go beyond the confines of the over-stretched hospital wards and into the comforts of the patient's home.

MedEthix further expanded the distribution of molnupiravir from the first four CSP grantees to over 80 health institutions and over 500 doctors as it successfully secured the emergency use authorization from the regulatory authority. The expanded access to affordable alternative treatment for Covid-19 benefited the Filipinos during the pandemic.